DAT

Synonyms

PKDYS1, DAT1, DAT, DA transporter, Sodium-dependent dopamine transporter, SLC6A3, Solute Carrier Family 6 (Neurotransmitter Transporter), Member 3, Dopamine Transporter 1, PKDYS, Dopamine Plasma Membrane Transport Proteins, Solute carrier family 6 member 3, Solute Carrier Family 6 (Neurotransmitter Transporter, Dopamine), Member 3, Dopamine Transporter

Description

DAT (Dopamine transporter) is an Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals. Regulator of light-dependent retinal hyaloid vessel regression, downstream of OPN5 signaling.The dopamine transporter (DAT) plays an important homeostatic role in the control of both the extracellular and intraneuronal concentrations of dopamine, thereby providing effective control over activity of dopaminergic transmission.

KO Status

F0

Drug Information

Launched drugs: 10
Drugs in clinical trials: 16
Latest Research Phase: Approved

Drug Name

Code

Phase

Company

Indications

Clinical Trials

Sydnocarb

MLR-1017

Approved

Teva

Mental Disorders

Dexmethylphenidate Hydrochloride

Approved

Novartis Pharma Ag

Neoplasms, Fatigue, Attention Deficit Disorder with Hyperactivity

Amineptine Hydrochloride

S-1694

Approved

Depression

Serdexmethylphenidate/Dexmethylphenidate

KP-484, KP-415, KP-879

Approved

Kempharm

Attention Deficit Disorder with Hyperactivity

Modafinil

CEP-1538, CRL-40476, CN-801, AFT-801

Approved

Sleepiness, Sleep Apnea, Obstructive, Attention Deficit Disorder with Hyperactivity, Disorders of Excessive Somnolence, Sleep Apnea Syndromes, Narcolepsy

Mazindol

42-548, AN-448, NLS-1001, SaH-42548

Approved

Novartis Pharma Ag

Attention Deficit Disorder with Hyperactivity, Obesity

Bupropion Hydrochloride

BW-323U66, CPI-300

Approved

Glaxosmithkline Plc

Depressive Disorder, Major, Depression, Attention Deficit Disorder with Hyperactivity, Smoking Cessation, Neoplasms, Depressive Disorder, Seasonal Affective Disorder

Solriamfetol

YKP-10A, R-228060

Approved

Sk Biopharmaceuticals

Disorders of Excessive Somnolence, Sleep Apnea, Obstructive, Parkinson Disease, Narcolepsy

Armodafinil

CEP-10952, CEP-10953, CRL-40982

Approved

Teva Pharmaceutical Industries Ltd

Drug-Related Side Effects and Adverse Reactions, Sleepiness, Depression, Schizophrenia, Brain Injuries, Traumatic, Bipolar Disorder, Fatigue, Sleep Disorders, Circadian Rhythm, Disorders of Excessive Somnolence, Sleep Apnea, Obstructive, Multiple Myeloma, Sleep Apnea Syndromes, Narcolepsy

Bupropion Hypochloride

Approved

Sigillata Ltd

References


Title

Authors

Source

A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs

Vandenbergh D.J., Persico A.M., Uhl G.R.,

Brain Res. Mol. Brain Res. 15:161-166(1992)

Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter

Giros B., el Mestikawy S., Godinot N., Zheng K., Han H., Yang-Feng T., Caron M.G.,

Mol. Pharmacol. 42:383-390(1992)

Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding

Pristupa Z.B., Wilson J.M., Hoffman B.J., Kish S.J., Niznik H.B.,

Mol. Pharmacol. 45:125-135(1994)

The consensus coding sequences of human breast and colorectal cancers

Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., Velculescu V.E.,

Science 314:268-274(2006)

Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia

Kurian M.A., Zhen J., Cheng S.Y., Li Y., Mordekar S.R., Jardine P., Morgan N.V., Meyer E., Tee L., Pasha S., Wassmer E., Heales S.J., Gissen P., Reith M.E., Maher E.R.,

J. Clin. Invest. 119:1595-1603(2009)

A population-specific HTR2B stop codon predisposes to severe impulsivity

Bevilacqua L., Doly S., Kaprio J., Yuan Q., Tikkanen R., Paunio T., Zhou Z., Wedenoja J., Maroteaux L., Diaz S., Belmer A., Hodgkinson C.A., Dell'osso L., Suvisaari J., Coccaro E., Rose R.J., Peltonen L., Virkkunen M., Goldman D.,

Nature 468:1061-1066(2010)

Structure and organization of the gene encoding human dopamine transporter

Kawarai T., Kawakami H., Yamamura Y., Nakamura S.,

Gene 195:11-18(1997)

Human dopamine transporter gene: coding region conservation among normal, Tourette's disorder, alcohol dependence and attention-deficit hyperactivity disorder populations

Vandenbergh D.J., Thompson M.D., Cook E.H., Bendahhou E., Nguyen T., Krasowski M.D., Zarrabian D., Comings D., Sellers E.M., Tyndale R.F., George S.R., O'Dowd B.F., Uhl G.R.,

Mol. Psychiatry 5:283-292(2000)

Evidence for linkage disequilibrium between the dopamine transporter and bipolar disorder

Greenwood T.A., Alexander M., Keck P.E., McElroy S., Sadovnick A.D., Remick R.A., Kelsoe J.R.,

Am. J. Med. Genet. 105:145-151(2001)

Sequence variation in the primate dopamine transporter gene and its relationship to social dominance

Miller-Butterworth C.M., Kaplan J.R., Shaffer J., Devlin B., Manuck S.B., Ferrell R.E.,

Mol. Biol. Evol. 25:18-28(2008)